PT  - JOURNAL ARTICLE
AU  - ZALYTE, EGLE
AU  - DEDONYTE, VERONIKA
AU  - KURLINKUS, BENEDIKTAS
AU  - SILEIKIS, AUDRIUS
AU  - SCHEMMER, PETER
AU  - VALIUS, MINDAUGAS
TI  - Establishment and Characterization of a New Pancreatic Ductal Adenocarcinoma Cell Line Capan-26
AID  - 10.21873/anticanres.14897
DP  - 2021 Mar 01
TA  - Anticancer Research
PG  - 1401--1406
VI  - 41
IP  - 3
4099  - http://ar.iiarjournals.org/content/41/3/1401.short
4100  - http://ar.iiarjournals.org/content/41/3/1401.full
SO  - Anticancer Res2021 Mar 01; 41
AB  - Background/Aim: Pancreatic ductal adenocarcinoma is one of the deadliest forms of human cancer. Since only a vast panel of cell lines can fully recapitulate disease heterogeneity, our aim was to establish a new pancreatic cancer cell line. Materials and Methods: Newly established pancreatic ductal adenocarcinoma cell line Capan-26 was characterized by assessing growth rate, tumor and stem cell marker expression, colony forming efficiency, mutations of KRAS and TP53 genes, karyotype and sensitivity to drug treatment. Results: Cell doubling time was 74 h. We detected CA19-9, CEACAM6, CD44, OCT4 and ZEB1 expression in Capan-26 cell line. Cells formed colonies in soft agar, have a deletion of KRAS exon 3 and a point mutation V172F in TP53 exon 5. They are a mixed aneuploid/polyploid population with high sensitivity to gemcitabine. Conclusion: Capan-26 is a unique cell line that may be used to study the mechanism of pancreatic cancer.